PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-26.65%
Negative revenue growth while CSIQ stands at 33.76%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-42.24%
Negative gross profit growth while CSIQ is at 72.33%. Joel Greenblatt would examine cost competitiveness or demand decline.
-90.10%
Negative EBIT growth while CSIQ is at 232.70%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-90.68%
Negative operating income growth while CSIQ is at 154.76%. Joel Greenblatt would press for urgent turnaround measures.
-78.32%
Negative net income growth while CSIQ stands at 1374.57%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-79.25%
Negative EPS growth while CSIQ is at 1357.14%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-78.57%
Negative diluted EPS growth while CSIQ is at 1257.14%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
6.18%
Share count expansion well above CSIQ's 4.13%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
-2.56%
Reduced diluted shares while CSIQ is at 8.85%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-361.62%
Negative OCF growth while CSIQ is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-675.31%
Negative FCF growth while CSIQ is at 0.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
320.41%
10Y revenue/share CAGR under 50% of CSIQ's 12716.87%. Michael Burry would suspect a lasting competitive disadvantage.
19.51%
5Y revenue/share CAGR under 50% of CSIQ's 255.81%. Michael Burry would suspect a significant competitive gap or product weakness.
-35.46%
Negative 3Y CAGR while CSIQ stands at 1.76%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-194.25%
Negative 10Y OCF/share CAGR while CSIQ stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-3372.51%
Negative 5Y OCF/share CAGR while CSIQ is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
6.13%
3Y OCF/share CAGR of 6.13% while CSIQ is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
130.22%
Below 50% of CSIQ's 7520.63%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
-31.05%
Negative 5Y net income/share CAGR while CSIQ is 105.58%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
107.18%
Below 50% of CSIQ's 519.11%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
-28.04%
Negative 5Y equity/share growth while CSIQ is at 4.64%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-31.98%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
74.34%
AR growth well above CSIQ's 16.68%. Michael Burry fears inflated revenue or higher default risk in the near future.
-1.99%
Inventory is declining while CSIQ stands at 17.34%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
12.95%
Asset growth above 1.5x CSIQ's 7.22%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
8.74%
Similar to CSIQ's 8.29%. Walter Schloss finds parallel capital usage or profit distribution strategies.
19.49%
Debt growth far above CSIQ's 5.51%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-0.99%
Our R&D shrinks while CSIQ invests at 14.32%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-3.29%
We cut SG&A while CSIQ invests at 20.59%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.